Yardena Samuels
Yardena Samuels
Verified email at
Cited by
Cited by
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels, Z Wang, A Bardelli, N Silliman, J Ptak, S Szabo, H Yan, ...
Science 304 (5670), 554-554, 2004
Genomic classification of cutaneous melanoma
R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ...
Cell 161 (7), 1681-1696, 2015
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
PF Robbins, YC Lu, M El-Gamil, YF Li, C Gross, J Gartner, JC Lin, JK Teer, ...
Nature medicine 19 (6), 747, 2013
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels, LA Diaz, O Schmidt-Kittler, JM Cummins, L DeLong, I Cheong, ...
Cancer cell 7 (6), 561-573, 2005
ASPP proteins specifically stimulate the apoptotic function of p53
Y Samuels-Lev, DJ O'Connor, D Bergamaschi, G Trigiante, JK Hsieh, ...
Molecular cell 8 (4), 781-794, 2001
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman, P Argani, Y Samuels, N Silliman, J Ptak, S Szabo, ...
Cancer biology & therapy 3 (8), 772-775, 2004
Mutations in a signalling pathway
DW Parsons, TL Wang, Y Samuels, A Bardelli, JM Cummins, L DeLong, ...
Nature 436 (7052), 792-792, 2005
Oncogenic PI3K and its role in cancer
Y Samuels, K Ericson
Current opinion in oncology 18 (1), 77-82, 2006
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
CH Huang, D Mandelker, O Schmidt-Kittler, Y Samuels, VE Velculescu, ...
Science 318 (5857), 1744-1748, 2007
Oncogenic mutations of PIK3CA in human cancers
Y Samuels, VE Velculescu
Cell cycle 3 (10), 1221-1224, 2004
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
X Wei, V Walia, JC Lin, JK Teer, TD Prickett, J Gartner, S Davis, ...
Nature genetics 43 (5), 442-446, 2011
Mutational inactivation of STAG2 causes aneuploidy in human cancer
DA Solomon, T Kim, LA Diaz-Martinez, J Fair, AG Elkahloun, BT Harris, ...
Science 333 (6045), 1039-1043, 2011
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human
D Bergamaschi, Y Samuels, NJ O'Neil, G Trigiante, T Crook, JK Hsieh, ...
Nature genetics 33 (2), 162-167, 2003
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas
DK Broderick, C Di, TJ Parrett, YR Samuels, JM Cummins, RE McLendon, ...
Cancer research 64 (15), 5048-5050, 2004
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
YC Lu, X Yao, JS Crystal, YF Li, M El-Gamil, C Gross, L Davis, ME Dudley, ...
Clinical Cancer Research 20 (13), 3401-3410, 2014
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
TD Prickett, NS Agrawal, X Wei, KE Yates, JC Lin, JR Wunderlich, ...
Nature genetics 41 (10), 1127-1132, 2009
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
K Tateishi, H Wakimoto, AJ Iafrate, S Tanaka, F Loebel, N Lelic, ...
Cancer cell 28 (6), 773-784, 2015
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ...
Science 374 (6575), 1632-1640, 2021
Oncogenic mutations of PIK3CA in human cancers
Y Samuels, T Waldman
Phosphoinositide 3-kinase in Health and Disease: Volume 2, 21-41, 2011
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53
D Bergamaschi, Y Samuels, A Sullivan, M Zvelebil, H Breyssens, A Bisso, ...
Nature genetics 38 (10), 1133-1141, 2006
The system can't perform the operation now. Try again later.
Articles 1–20